Pathogenic germline variants in BRCA1 and BRCA2 are prevalent in patients with CCA, but the pathogenesis of BRCA1/2 variants in driving this cancer type and the role of targeted therapy such as PARP inhibitors remain poorly studied in CCA compared with other cancer types such as ovarian and breast cancer.127. This evidence concerns the gene BRCA2 and cancer.